Hereditary melanoma

FDA-Approved Treatments

• Encorafenib + binimetinib (Brand name: Braftovi + Mektovi) - Manufactured by Array BioPharma, Inc.
  FDA-approved indication: June 2018, approved in combination for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
  
• Pembrolizumab (Brand name: Keytruda) - Manufactured by Merck, Sharp & Dohme Corp
  FDA-approved indication: Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
  National Library of Medicine Drug Information Portal
  Medline Plus Health Information
• Trametinib (Brand name: Mekinist) - Manufactured by GlaxoSmithKline, LLC
  FDA-approved indication: Treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test.
  National Library of Medicine Drug Information Portal
• Trametinib and dabrafenib combination (Brand name: Mekinist And Tafinlar) - Manufactured by Novartis Pharmaceuticals Corporation
  FDA-approved indication: April 2018 approved combination for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.
  
• Nivolumab (Brand name: Opdivo) - Manufactured by Bristol-Myers Squibb Co
  FDA-approved indication: Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. And treatment of patients with melanoma with involvement of lymph nodes or metestatic disease who have undergone complete resection.
  National Library of Medicine Drug Information Portal
  Medline Plus Health Information
• Aldesleukin (Brand name: Proleukin) - Manufactured by Chiron Corporation
  FDA-approved indication: Treatment of adults with metastatic melanoma.
  National Library of Medicine Drug Information Portal
  Medline Plus Health Information
• Peginterferon Alfa-2b (Brand name: Sylatron) - Manufactured by Schering/Merck
  FDA-approved indication: Adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy
  National Library of Medicine Drug Information Portal
• Dabrafenib (Brand name: Tafinlar) - Manufactured by GlaxoSmithKline, LLC
  FDA-approved indication: Treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA approved test.
  National Library of Medicine Drug Information Portal
• Technetium Tc99m sulfur colloid injection, lyophilized (Brand name: Technetium Tc99m Sulfur Colloi) - Manufactured by Pharmalucence, Inc.
  FDA-approved indication: Localization of lymph nodes draining a primary tumor in patients with melanoma when used with a hand-held gamma counter
  National Library of Medicine Drug Information Portal
• Ipilimumab (Brand name: Yervoy) - Manufactured by Bristol-Myers Squibb Pharmaceutical
  FDA-approved indication: Treatment of unresectable or metastatic melanoma for patients 12 years old and up.
  National Library of Medicine Drug Information Portal
  Medline Plus Health Information

Support and advocacy groups can help you connect with other patients and families, and they can provide valuable services. Many develop patient-centered information and are the driving force behind research for better treatments and possible cures. They can direct you to research, resources, and services. Many organizations also have experts who serve as medical advisors or provide lists of doctors/clinics. Visit the group’s website or contact them to learn about the services they offer. Inclusion on this list is not an endorsement by GARD.

Living with a genetic or rare disease can impact the daily lives of patients and families. These resources can help families navigate various aspects of living with a rare disease.

These resources provide more information about this condition or associated symptoms. The in-depth resources contain medical and scientific language that may be hard to understand. You may want to review these resources with a medical professional.